Exogenous Hormone Use and Meningioma Risk
Updated: Nov 3
Archived conference abstract — the research and affiliations below reflect the original event submission. Claims are attributed to the authors; this is not a peer-reviewed journal article or current clinical guidance.
International Live Conference on Drug Discovery Date: March 16, 2024 Venue: Online Conference
Title: Exogenous hormone use and meningioma risk
Author: Dr. Habchi Nawel, Mustapha PACHA Hospital Email Id: nawelmedbio@yahoo.fr
Abstract:
Meningiomas are brain tumors that occur in the second half of life, with 76% of cases occurring after 50. Causes include genetics, environmental exposure to ionizing radiation, and hormonal differences. Meningiomas may be influenced by estrogen and progesterone, which have a positive association with breast cancer, tumor growth during pregnancy, and attenuation after menopause and upon cessation of treatment. Progesterone prescriptions cause meningiomas to grow rapidly and increase the risk of recurrence. Studies confirm that meningiomas are hormone-sensitive, with 70% expressing progesterone receptors and 30% expressing estrogen receptors. Prolonged administration of certain progestins, such as cyproterone, promegestone, and normegestol, can lead to meningiomas regression. Hormone replacement therapy users have an increased risk of meningiomas, but no established recommendations exist.
Explore the speaker profile
Related upcoming conferences
Explore related subjects in the upcoming programme. Historical contributions above are separate from the future speaker line-up.
